The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Official Title: An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Study ID: NCT01034410
Brief Summary: This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UCLA, Los Angeles, California, United States
Weill Medical College of Cornell University, New York, New York, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Royal North Shore Hospital, St Leonards, New South Wales, Australia
Westmead Hospital, Westmead, New South Wales, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
Royal Perth Hospital, Perth, Western Australia, Australia
Christchurch Hospital, Christchurch, , New Zealand
Changhua Christian Hospial, Changhua City, Changhua Country, Taiwan
China Medical University Hospital, Taichung City, , Taiwan
Tri-Service General Hospital, Taipei City, , Taiwan
Taipei Veterans General Hospital, Taipei, , Taiwan
National Taiwan University Hospital, Taipei, , Taiwan
Name: Rob Stuart, MD
Affiliation: Medical University of South Carolina
Role: PRINCIPAL_INVESTIGATOR